BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33708175)

  • 1. L-T4 Therapy in Enteric Malabsorptive Disorders.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Antonelli A
    Front Endocrinol (Lausanne); 2021; 12():626371. PubMed ID: 33708175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update.
    Fallahi P; Ferrari SM; Ruffilli I; Ragusa F; Biricotti M; Materazzi G; Miccoli P; Antonelli A
    Expert Opin Drug Deliv; 2017 May; 14(5):647-655. PubMed ID: 27552635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine.
    Antonelli A; Elia G; Ragusa F; Paparo SR; Cavallini G; Benvenga S; Ferrari SM; Fallahi P
    Front Endocrinol (Lausanne); 2021; 12():633587. PubMed ID: 33790863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study.
    Fallahi P; Ferrari SM; Antonelli A
    Endocrine; 2016 Jun; 52(3):597-601. PubMed ID: 26721663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM.
    Fallahi P; Ferrari SM; Antonelli A
    Endocr Pract; 2017 Feb; 23(2):170-174. PubMed ID: 27849377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The administration of L-thyroxine as soft gel capsule or liquid solution.
    Vita R; Fallahi P; Antonelli A; Benvenga S
    Expert Opin Drug Deliv; 2014 Jul; 11(7):1103-11. PubMed ID: 24896369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shift from Levothyroxine Tablets to Liquid Formulation at Breakfast Improves Quality of Life of Hypothyroid Patients.
    Guglielmi R; Grimaldi F; Negro R; Frasoldati A; Misischi I; Graziano F; Cipri C; Guastamacchia E; Triggiani V; Papini E
    Endocr Metab Immune Disord Drug Targets; 2018; 18(3):235-240. PubMed ID: 29376496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations.
    Vita R; Saraceno G; Trimarchi F; Benvenga S
    Endocrine; 2013 Feb; 43(1):154-60. PubMed ID: 22932947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation.
    Fallahi P; Ferrari SM; Camastra S; Politti U; Ruffilli I; Vita R; Navarra G; Benvenga S; Antonelli A
    Obes Surg; 2017 Jan; 27(1):78-82. PubMed ID: 27272506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series.
    Fallahi P; Ferrari SM; Ruffilli I; Antonelli A
    BMC Gastroenterol; 2016 Feb; 16():22. PubMed ID: 26965518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis.
    Laurent I; Tang S; Astère M; Wang KR; Deng S; Xiao L; Li QF
    Endocrine; 2018 Jul; 61(1):28-35. PubMed ID: 29572710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia.
    Morini E; Catalano A; Lasco A; Morabito N; Benvenga S
    Endocrine; 2019 Sep; 65(3):569-579. PubMed ID: 30919287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral liquid levothyroxine treatment at breakfast: a mistake?
    Cappelli C; Pirola I; Gandossi E; Formenti A; Castellano M
    Eur J Endocrinol; 2014 Jan; 170(1):95-9. PubMed ID: 24123095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral liquid L-thyroxine (L-t4) may be better absorbed compared to L-T4 tablets following bariatric surgery.
    Pirola I; Formenti AM; Gandossi E; Mittempergher F; Casella C; Agosti B; Cappelli C
    Obes Surg; 2013 Sep; 23(9):1493-6. PubMed ID: 23824980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study.
    Fallahi P; Ferrari SM; Materazzi G; Ragusa F; Ruffilli I; Patrizio A; Miccoli P; Antonelli A
    Laryngoscope Investig Otolaryngol; 2018 Oct; 3(5):405-408. PubMed ID: 30410995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to levothyroxine in a bariatric surgery patient: an indication for liquid formulation?
    Hommel C; Delgrange E
    Acta Clin Belg; 2017 Feb; 72(1):72-75. PubMed ID: 27362875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine.
    Cellini M; Santaguida MG; Gatto I; Virili C; Del Duca SC; Brusca N; Capriello S; Gargano L; Centanni M
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1454-8. PubMed ID: 24796930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Levothyroxine Therapy in Patients With Hypothyroidism.
    Antonelli A; Wartofsky L; Miccoli P
    Front Endocrinol (Lausanne); 2021; 12():734895. PubMed ID: 34354674
    [No Abstract]   [Full Text] [Related]  

  • 19. Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance.
    Jojima T; Shinzawa T; Ohira E; Sakurai S; Tomaru T; Iijima T; Kogai T; Usui I; Aso Y
    Endocr J; 2022 Aug; 69(8):941-945. PubMed ID: 35249899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The different requirement of L-T4 therapy in congenital athyreosis compared with adult-acquired hypothyroidism suggests a persisting thyroid hormone resistance at the hypothalamic-pituitary level.
    Bagattini B; Cosmo CD; Montanelli L; Piaggi P; Ciampi M; Agretti P; Marco GD; Vitti P; Tonacchera M
    Eur J Endocrinol; 2014 Nov; 171(5):615-21. PubMed ID: 25305309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.